These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29018684)

  • 41. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
    Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
    Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Prospective Pilot Study.
    Barikian A; Salti H; Safar A; Mahfoud ZR; Bashshur ZF
    Retina; 2017 Jul; 37(7):1337-1344. PubMed ID: 27768640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
    Nomura Y; Yanagi Y
    Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Griffin DR; Richmond PP; Olson JC
    J Ophthalmol; 2014; 2014():497178. PubMed ID: 25505976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab.
    Lim RH; Gupta B; Simcock P
    Int J Ophthalmol; 2017; 10(3):423-426. PubMed ID: 28393034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
    Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
    Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration.
    Kano M; Sekiryu T; Sugano Y; Oguchi Y; Ojima A; Itagaki K; Saito M
    Clin Ophthalmol; 2015; 9():2049-56. PubMed ID: 26604674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
    Lazzeri S; Ripandelli G; Sartini MS; Parravano M; Varano M; Nardi M; Di Desidero T; Orlandi P; Bocci G
    Angiogenesis; 2015 Oct; 18(4):397-432. PubMed ID: 26346237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
    Amaro MH; Roller AB
    Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Electrophysiological study of the visual pathway in anti-VEGF therapy of neovascular age-related macular degeneration combined with glaucoma].
    Smirnova TV; Rud'ko AS; Andreeva IV; Karpilova MA
    Vestn Oftalmol; 2019; 135(5):38-45. PubMed ID: 31714511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases].
    Maringe E; Letesson E; Duncombe A; Muraine M; Genevois O
    J Fr Ophtalmol; 2016 Mar; 39(3):255-60. PubMed ID: 26995074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
    ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
    Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.